Channavix Therapeutics is focused on developing innovative, non-addictive, non-opioid analgesics that offer prolonged pain relief through local administration. Their research targets both acute and chronic pain conditions, catering to human and veterinary markets. The company is advancing two primary programs, each utilizing unique mechanisms of action to mitigate pain without the risks associated with traditional analgesics. These programs are characterized by patented technologies, genetically validated targets, and a commitment to ensuring no neurotoxicity while providing multi-week analgesia.

The first program centers on the inhibition of the NaV1.8 ion channel through the targeting of the Magi1 scaffolding protein, which is crucial for anchoring NaV1.8 at the cell surface. This approach has been validated in both in vitro and in vivo studies, demonstrating its efficacy in reducing pain signaling. The second program focuses on inhibiting the release of neuropeptides, such as CGRP and Substance P, in response to pain stimuli. This mechanism aims to prevent neuron hyperexcitability and disrupt the pain signaling cycle at its source, effectively targeting peripheral nerves while preserving motor control and normal sensation.

United States

Channavix Therapeutics, LLC is developing a portfolio of novel, non-addictive, non-opioid analgesics that provide multi-week pain relief with local administration. The business and scientific team that has been assembled for Channavix has a long history of working in the field of pain management and drug development. Channavix is dedicated to the discovery of novel therapeutics for neurological disorders such as pain, with a mission to improve patient outcomes and address the global opioid problem.

Channavix Therapeutics

Company Details